Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · IEX Real-Time Price · USD
3.200
+0.140 (4.58%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Aquestive Therapeutics Revenue
Aquestive Therapeutics had revenue of $51.50M in the twelve months ending March 31, 2024, with 10.65% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.05M with 8.25% year-over-year growth. In the year 2023, Aquestive Therapeutics had annual revenue of $50.58M with 6.09% growth.
Revenue (ttm)
$51.50M
Revenue Growth
+10.65%
P/S Ratio
5.66
Revenue / Employee
$381,496
Employees
135
Market Cap
291.32M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
Dec 31, 2019 | 52.61M | -14.82M | -21.98% |
Dec 31, 2018 | 67.43M | 512.00K | 0.77% |
Dec 31, 2017 | 66.92M | 15.13M | 29.22% |
Dec 31, 2016 | 51.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AngioDynamics | 324.01M |
Tactile Systems Technology | 276.67M |
Akebia Therapeutics | 187.23M |
Alimera Sciences | 90.22M |
Poseida Therapeutics | 82.50M |
Adaptimmune Therapeutics | 18.36M |
Verrica Pharmaceuticals | 8.91M |
Orchestra BioMed Holdings | 2.22M |
AQST News
- 25 days ago - Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - GlobeNewsWire
- 7 weeks ago - Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities - GlobeNewsWire
- 2 months ago - Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference - GlobeNewsWire
- 2 months ago - Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology - GlobeNewsWire
- 4 months ago - Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Aquestive Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire